Browse studies

Find your next paid study

172 recruiting studies matching your filters

A Phase II Trial of MOnaliZumab in Combination With durvAlumab (MEDI4736) for tReatmenT of Small Cell Lung Cancer (MOZART)

This study has 2 cohorts: MOZART-ES cohort (for extensive-stage SCLC) and MOZART-LS cohort (for limited-stage SCLC). MOZART-ES cohort: Study treatment will co…

Small Cell Lung CancerSCLCExtensive Stage Small Cell Lung Cancer+1 more

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Hirva MamdaniNCT05903092

Phase 3

A Randomized, Double-blind, Phase 3 Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib (RMC-9805) as First Line Treatment in Patients With Metastatic Non-squamous RAS G12D-Mutated Non-small Cell Lung Cancer (RASolve 308)

The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with pembrolizumab and platinum-based…

NSCLCNon-small Cell Lung CancerNon-Small Cell Lung Cancer NSCLC+4 more

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Revolution Medicines, Inc.NCT07777822

Phase 2

GCC 2545- Improving Post-Radiotherapy Respiratory Function Through Sparing Serial and Parallel Components in the Lung

Decreased respiratory function is a common side effect experienced by non-small cell lung cancer (NSCLC) patients who receive radiation therapy. In current cli…

Lung Cancer (NSCLC)Radiation

Estimated

~$75 – $2,000

Actual pay is set by the research site.

University of Maryland, BaltimoreNCT07679607

Phase 3

A Randomized, Double-Blind, Placebo-Controlled, Multi-Regional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy

The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use…

Limited-stage Small Cell Lung Cancer (LS-SCLC)

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Shanghai Junshi Bioscience Co., Ltd.NCT06095583